New drug trial targets Alzheimer's risk in down syndrome
NCT ID NCT06911944
Summary
This study is testing whether the drug donanemab can reduce the buildup of a harmful protein called amyloid in the brains of adults with Down syndrome. About 60 participants, aged 35-50, will receive monthly infusions of either donanemab or a placebo for one year, followed by an optional second year. The main goals are to see if the drug lowers brain amyloid levels and is safe and well-tolerated in this population.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.